Anne Beal Acquires 196 Shares of GSK (LON:GSK) Stock

Key Points

• Anne Beal bought 196 shares of GSK on March 20 at an average price of GBX 5,179, for a total of £10,150.84.
• Shares traded down to GBX 1,939 midday with a market cap of £77.78 billion, a P/E of 13.97, and a 52‑week range of GBX 1,242.50–2,282.
• Analysts are mixed — the consensus is an "Hold" with an average target of GBX 1,917.86 (three Buy, three Hold, one Sell), and several firms recently adjusted price targets.

GSK plc (LON:GSK - Get Free Report) insider Anne Beal bought 196 shares of GSK stock in a transaction on Friday, March 20th. The stock was purchased at an average price of GBX 5,179 per share, for a total transaction of £10,150.84.

GSK Trading Down 0.6%

Shares of LON GSK traded down GBX 11.50 during midday trading on Monday, reaching GBX 1,939. 886,705,000 shares of the stock were exchanged, compared to its average volume of 25,118,266. The company has a market capitalization of £77.78 billion, a P/E ratio of 13.97, a P/E/G ratio of 1.24 and a beta of 0.32. GSK plc has a 52-week low of GBX 1,242.50 and a 52-week high of GBX 2,282. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 108.20. The stock has a 50 day moving average price of GBX 2,024.84 and a 200-day moving average price of GBX 1,817.34.

GSK (LON:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, February 4th. The company reported GBX 172 earnings per share (EPS) for the quarter. GSK had a net margin of 17.50% and a return on equity of 37.19%. Equities research analysts expect that GSK plc will post 175.980975 earnings per share for the current fiscal year.

Analysts Set New Price Targets

GSK has been the topic of a number of recent analyst reports. Shore Capital Group reissued a "buy" rating and set a GBX 2,300 price target on shares of GSK in a research note on Wednesday, February 4th. Citigroup lifted their price objective on GSK from GBX 1,900 to GBX 2,250 and gave the company a "buy" rating in a research report on Monday, February 9th. JPMorgan Chase & Co. reiterated an "underweight" rating on shares of GSK in a research note on Wednesday, January 7th. UBS Group reiterated a "neutral" rating and set a GBX 1,940 target price on shares of GSK in a research report on Friday, January 23rd. Finally, Deutsche Bank Aktiengesellschaft raised their price target on GSK from GBX 1,600 to GBX 1,675 and gave the stock a "hold" rating in a research note on Thursday, January 15th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of GBX 1,917.86.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.